Migraine and Endothelial Dysfunction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01388699|
Recruitment Status : Unknown
Verified June 2011 by Charite University, Berlin, Germany.
Recruitment status was: Recruiting
First Posted : July 7, 2011
Last Update Posted : July 7, 2011
|Condition or disease|
|Migraine With Aura|
Our objectives were to determine whether novel endothelial function methods and novel markers of endothelial activation are associated with migraine in female migraineurs with aura.
Migraine is an independent risk factor for stroke, especially in young women with aura symptoms. Endothelial dysfunction is a risk factor for cardiovascular diseases. Recent studies suggest that there is a link between migraine with aura and endothelial activation, dysfunction and impaired vascular reactivity.
In this case-control study the investigators examine several novel biomarkers of endothelial function such as endothelial progenitor cells and endothelial microparticles as well as novel methods such as reactive hyperemic peripheral arterial tonometry in female migraineurs with aura and age-matched controls.
|Study Type :||Observational|
|Estimated Enrollment :||60 participants|
|Observational Model:||Case Control|
|Official Title:||Migraine and Endothelial Dysfunction|
|Study Start Date :||October 2010|
|Estimated Primary Completion Date :||August 2011|
|Estimated Study Completion Date :||September 2011|
female migraineurs with aura
healthy women without headache syndrome
- Endothelial Microparticles [ Time Frame: baseline ]Levels of endothelial microparticlel in the peripheral blood using flow cytometry
- Levels of circulating Endothelial Progenitor Cells [ Time Frame: baseline ]Levels of cEPC (CD34+/CD133+/VGF2R/CD31) in % of mononuclear cells using flow cytometry
- Digital pulse volume change [ Time Frame: baseline ]Digital pulse volume change (with RH PAT as non invasive measurement (PAT-ratio; ENDOPAT, Itamar Medical Ltd.) for non-invasive, peripheral endothelial function
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01388699
|Contact: Matthias Endres, MDfirstname.lastname@example.org|
|Contact: Thomas G Liman, MDemail@example.com|
|Center for Stroke Research Berlin||Recruiting|
|Berlin, Germany, 10117|
|Contact: Thomas G Liman, MD 004930450560643 firstname.lastname@example.org|
|Principal Investigator: Matthias Endres, MD|
|Sub-Investigator: Thomas G Liman, MD|
|Principal Investigator:||Matthias Endres, MD||Center for Stroke Research Berlin, Charité Campus Mitte|